# Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer

> **NCT06599216** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Harbin Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer
- HR+/HER2- Breast Cancer

## Interventions

- **DRUG:** Adebrelimab+Dalpciclib+Standard Endocrine Therapy

## Key facts

- **NCT ID:** NCT06599216
- **Lead sponsor:** Harbin Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-08
- **Primary completion:** 2026-03-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06599216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06599216, "Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06599216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*